News | Contrast Media | January 19, 2018

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents

Focus will be on hospital-based products that could benefit from reduced renal toxicity

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity. Through this new, internally-funded program, Ligand intends to advance products toward proof-of-concept, followed by selling or out-licensing them for further development and commercialization. The program will leverage Ligand’s patented Captisol technology, as well as data and intellectual property obtained through its acquisition of Verrow Pharmaceuticals, a privately-held Lenexa, Kansas-based medical invention company that Ligand acquired in January 2018 for $2 million in cash plus earnouts.

Ligand CEO John Higgins explained that contrast agents are an important component of the diagnostic imaging market, however they can be toxic and are known to cause kidney damage in some patients. He added that Captisol is a specialized cyclodextrin that plays a role in protecting kidneys from the damaging effects of these agents. Captisol-enabled (CE) iohexol, marketed as Omnipaque by GE Healthcare, has been shown to prevent nephrotoxicity by more than 50 percent in animal models.1

The company said the initial internal program is focused on a CE formulation of iohexol given the large global market, lack of alternatives and focused development path for use in the cardiovascular imaging setting. The initial CE-iohexol program will focus on partnering-enabling studies, with an estimated $6 million of program spend by Ligand over approximately three years.

For more information: www.ligand.com

References

1. Rowe ES, et al. Journal of Neuroimaging 2016; 26(5):511-8

Related Content

Feature | Cardiac Imaging | By Ronny Shalev, Ph.D.

Artificial intelligence’s (AI) applicability in cardiac imaging is rapidly growing and was a major topic of discussion ...

Home June 28, 2022
Home
News | Cardiac Imaging

June 24, 2022 — The Radiological Society of North America (RSNA) reports that Coronary Artery Calcium (CAC) scoring with ...

Home June 24, 2022
Home
News | Cardiac Imaging

June 23, 2022 — New research from the Smidt Heart Institute at Cedars-Sinai shows for the first time that the path ...

Home June 23, 2022
Home
News | Cardiac Imaging

May 2, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), routine visual ordinal coronary artery calcium ...

Home May 02, 2022
Home
News | Cardiac Imaging

April 11, 2022 — Radiation to the heart during treatment for locally advanced lung cancer is associated with an ...

Home April 11, 2022
Home
News | Cardiac Imaging
February 21, 2022 – Acute coronary syndromes (such as heart attacks) and strokes are a leading cause of morbidity and ...
Home February 21, 2022
Home
News | Cardiac Imaging
February 21, 2022 – Researchers at Michigan Medicine have found a novel method of measuring growth in the body’s largest ...
Home February 21, 2022
Home
News | Cardiac Imaging

February 18, 2022 — GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) ...

Home February 18, 2022
Home
Videos | Cardiac Imaging

Interview with Campbell Rogers, M.D., chief medical officer of HeartFlow which has developed a CT image-based fractional ...

Home February 01, 2022
Home
Videos | Cardiac Imaging

American Society of Nuclear Cardiology (ASNC) President Dennis Calnon, M.D., MASNC, FASE, FSCCT, director of cardiac ...

Home February 01, 2022
Home
Subscribe Now